

INFECTION CONTROL^{AND}

HOSPITAL EPIDEMIOLOGY

Volume 11, Number 3 • March 1990

EDITORIAL

Medical Ostriches

Douglas R. LaBrecque, MD

126

ORIGINAL ARTICLES

Hepatitis B: Perceptions, Knowledge and Vaccine Acceptance Among Registered Nurses in High-Risk Occupations in a University Hospital

Michael R. Spence, MD, MPH;
Georgia P. Dash, MS, CIC

129

Nosocomial Infection Caused by *Xanthomonas maltophilia*: A Case-Control Study of Predisposing Factors

Linda S. Elting, DrPH;
Nancy Khardori, MD, PhD;
Gerald P. Bodey, MD; Victor Fainstein, MD

134

Alcohol for Surgical Scrubbing?

Elaine L. Larson, PhD;
Arlene M. Butz, ScD;
Donna L. Gullette, MSN;
Barbara A. Laughon, PhD

139

Brief Report: The Utilization of Influencing Tactics for the Implementation of Infection Control Policies

W.H. Seto, MD; S.G. Ong, MD;
T.Y. Ching, RN; S.H. Ng, PhD;
Y.B. Chu, BSc; W.H. Yung, MD;
L.M. Ho, BSc

144

SPECIAL COMMENTARY

Contributions of Epidemiology to Quality Assessment and Monitoring

Avedis Donabedian, MD

117

CLINICAL PHARMACOLOGY OF ANTIBIOTICS

Empiric Antimicrobial Therapy in the Febrile Granulocytopenic Patient

Walter T. Hughes, MD

151

EMPORIATRICS

Emporiatics: The Study of Diseases in Travelers

Mary D. Nettleman, MD

157

SHEA NEWSLETTER

161

The Official Journal of The Society of Hospital Epidemiologists of America

From SmithKline Biologicals/SK&F

Engerix-B[®]

Hepatitis B Vaccine (Recombinant)

0, 1, 2 Month Dosing Regimen for Certain Populations*

**20 mcg recombinant
dose helps to ensure
immune response
in adult patients of
all ages**

**Choice of dosing
regimens**

| |
|--|
| Adult dose (mcg) |
| Standard dosing regimen (0, 1 and 6 months) |
| New 0, 1, 2 month dosing regimen for certain populations* |
| Published efficacy data: Neonates born of infected mothers† |
| VACTRAC™—computer software for vaccination tracking and compliance |
| Bar-coded, unit-dose vials |
| Lowest cost per dose ² |

*For those recently exposed to the virus (including needlestick exposure), certain travelers to high-risk areas, and neonates born of infected mothers. When prolonged maintenance of protective antibody titers is desired, a booster dose at month 12 is recommended.

†Hepatitis B Vaccine (Recombinant), MSD.

‡Please see brief summary of prescribing information on adjacent page for a complete listing of adverse reactions, contraindications, warnings and precautions.

©SmithKline Beckman Corporation, 1990

Lowest Cost Per Dose²

Extensively Tested and Well Tolerated[‡]


State-of-the-art recombinant technology

10 million doses distributed in over 80 countries³

Switch to 'Engerix-B'

Can be used to complete a course of vaccination initiated with another hepatitis B vaccine^{3,4}

| Engerix-B [®] | Recombivax HB [®] † |
|------------------------|------------------------------|
| 20 | 10 |
| Yes | Yes |
| Yes | No |
| Yes | Yes |
| Yes | No |
| Yes | No |
| Yes | No |



Manufactured by
SmithKline Biologicals
Rixensart, Belgium

Distributed by
SmithKline French Laboratories
Philadelphia, PA 19101

Engerix-B®

Hepatitis B Vaccine (Recombinant)

See complete prescribing information in SK&F literature or PDR. The following is a brief summary.

INDICATIONS AND USAGE: 'Engerix-B' is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. Immunization is recommended in persons of all ages, especially those who are or will be, at increased risk of exposure to hepatitis B virus.

CONTRAINDICATIONS: Hypersensitivity to yeast or any other component of the vaccine is a contraindication for use of the vaccine.

WARNINGS: Do not give intramuscular injections to patients experiencing hypersensitivity after an 'Engerix-B' injection. (See CONTRAINDICATIONS.)

Hepatitis B has a long incubation period. Hepatitis B vaccination may not prevent hepatitis B infection in individuals who had an unrecognized hepatitis B infection at the time of vaccine administration. Additionally, it may not prevent infection in individuals who do not achieve protective antibody titers.

PRECAUTIONS: General: As with any parenteral vaccine, keep epinephrine available for use in case of anaphylaxis or anaphylactoid reaction. As with any vaccine, delay administration, if possible, in persons with any febrile illness of active infection.

Pregnancy: Pregnancy Category C. Animal reproduction studies have not been conducted with 'Engerix-B'. It is also not known whether 'Engerix-B' can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Give 'Engerix-B' to a pregnant woman only if clearly needed.

Nursing Mothers: It is not known whether 'Engerix-B' is excreted in human milk. Because many drugs are excreted in human milk, use caution when giving 'Engerix-B' to a nursing woman.

Pediatric Use: 'Engerix-B' has been shown to be well tolerated and highly immunogenic in infants and children of all ages. Newborns also respond well; maternally transferred antibodies do not interfere with the active immune response to the vaccine.

ADVERSE REACTIONS: 'Engerix-B' is generally well tolerated. During clinical studies involving over 10,000 individuals distributed over all age groups, no serious adverse reactions attributable to vaccine administration were reported. As with any vaccine, however, it is possible that expanded commercial use of the vaccine could reveal rare adverse reactions not observed in clinical studies.

Ten double-blind studies involving 2,252 subjects showed no significant difference in the frequency or severity of adverse experiences between 'Engerix-B' and plasma-derived vaccines. In 36 clinical studies a total of 13,495 doses of 'Engerix-B' were administered to 5,071 healthy adults and children who were initially seronegative for hepatitis B markers and healthy neonates. All subjects were monitored for 4 days post-administration. Frequency of adverse experiences tended to decrease with successive doses of 'Engerix-B'. Using a symptom checklist,* the most frequently reported adverse reactions were injection site soreness (22%), and fatigue* (14%). Other reactions are listed below.

Incidence 1% to 10% of Injections: Induration; erythema; swelling; fever (> 37.5°C); headache; dizziness.

*Parent or guardian completed forms for children and neonates. Neonatal checklist did not include headache, fatigue or dizziness.

Incidence < 1% of Injections: Pain; pruritus; ecchymosis; sweating; malaise; chills; weakness; flushing; tingling; hypotension; influenza-like symptoms; upper respiratory tract illnesses; nausea; anorexia; abdominal pain; cramps; vomiting; constipation; diarrhea; lymphadenopathy; pain/stiffness in arm, shoulder or neck; arthralgia; myalgia; back pain; rash; urticaria; petechiae; erythema; somnolence; insomnia; irritability; agitation.

Additional adverse experiences have been reported with the commercial use of 'Engerix-B' outside the United States. Those listed below are to serve as alerting information to physicians: Anaphylaxis; erythema multiforme including Stevens-Johnson syndrome; angioedema; arthritis; tachycardia/palpitations; bronchospasm including asthma-like symptoms; abnormal liver function tests; migraine; syncope; paresis; neuropathy including hypoesthesia, paresthesia, Guillain-Barré syndrome and Bell's palsy; transverse myelitis; thrombocytopenia; eczema; purpura; herpes zoster; vertigo; conjunctivitis; keratitis; visual disturbances.

Potential Adverse Experiences: In addition, certain other adverse experiences not observed with 'Engerix-B' have been reported with Hepavax B®† and/or Recombivax HB®‡. Those listed below are to serve as alerting information to physicians: optic neuritis.

HOW SUPPLIED: 20 mcg/mL in Single-Dose Vials in packages of 11, 10 and 25 vials.

NOC 0007-3860-01 (package of 1)
NDC 0007-3860-11 (package of 10)
NOC 0007-3860-16 (package of 25)

10 mcg/0.5 mL in Single-Dose Vials in packages of 1 vial.

NDC 0007-3859-01 (package of 1)

† plasma-derived Hepatitis B Vaccine, MSD.
‡ yeast-derived Hepatitis B Vaccine, MSD

Manufactured by **SmithKline Biologicals**, Rixensart, Belgium
Distributed by **SmithKline Beecham Laboratories**
Off of SmithKline Beecham Corp., Philadelphia, PA 19101

Date of issuance Aug. 1989

BRS-EBL6

© SmithKline Beecham Corporation, 1989

Engerix-B is a registered trademark of SmithKline Beecham Corporation

References:


1. Poovorawan Y, Sanpavats P, Pongpunlert W, et al: Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. *JAMA* 1989; 261(22):3278-3281.
2. Based on Medi-Span® Hospital Formulary Pricing Guide, December 1989.
3. Data on file, SK&F.
4. Bush L, Moonsammy G, Boscia J: Evaluation of initiating a hepatitis B vaccination schedule with one vaccine and completing it with another. *Hepatology* 1989; 10:689.


HATS OFF TO FIRST CLASS SERVICE


At SLACK incorporated we believe our subscribers are first class people. That's why we do everything possible to publish first class journals. And, that's why we maintain a TOLL-FREE CUSTOMER SERVICE HOTLINE. For the first class customer service you deserve, call:


1-800-257-8290


Talk to a SLACK Customer Service Representative about:

 Subscriptions. Subscribing by phone is quick and easy; it only takes a minute and Visa and Mastercard are accepted.

 Renewals. Early subscription renewal helps avoid possible interruptions in service.

 Change of Address. Please notify us four weeks in advance to assure prompt delivery to your new address.

 Questions or Problems. Delivery problems or questions about your subscriptions can be handled instantly.



SLACK

6900 Grove Road,
Thorofare, NJ 08086

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

| | | |
|--------------------------|--|-------------------------------|
| EDITORIAL | Medical Ostriches Douglas R. LaBrecque, MD | 126 |
| ORIGINAL ARTICLES | Hepatitis B: Perceptions, Knowledge and Vaccine Acceptance Among Registered Nurses in High-Risk Occupations in a University Hospital Michael R. Spence, MD, MPH; Georgia P. Dash, MS, CIC | 129 |
| | Nosocomial Infection Caused by <i>Xanthomonas maltophilia</i>: A Case-Control Study of Predisposing Factors Linda S. Elting, DrPH; Nancy Khardori, MD, PhD; Gerald P. Bodey, MD; Victor Fainstein, MD | 134 |
| | Alcohol for Surgical Scrubbing? Elaine L. Larson, PhD; Arlene M. Butz, ScD; Donna L. Gullette, MSN; Barbara A. Laughon, PhD | 139 |
| | Brief Report: The Utilization of Influencing Tactics for the Implementation of Infection Control Policies W.H. Seto, MD; S.G. Ong, MD; T.Y. Ching, RN; S.H. Ng, PhD; Y.B. Chu, BSc; W.H. Yung, MD; L.M. Ho, BSc | 144 |
| SPECIAL SECTIONS | Special Commentary Contributions of Epidemiology to Quality Assessment and Monitoring Avedis Donabedian, MD | 117 |
| | Clinical Pharmacology of Antibiotics Empiric Antimicrobial Therapy in the Febrile Granulocytopenic Patient Walter T. Hughes, MD | 151 |
| | Emporiatics Emporiatics: The Study of Diseases in Travelers Mary D. Nettleman, MD | 157 |
| DEPARTMENTS | <i>SHEA</i> Newsletter 161 | Calendar of Events 164 |
| | Classified Marketplace 163 | |

The ideas and opinions expressed by contributing authors do not necessarily reflect those of the editors or publisher.

Publisher: Infection Control and Hospital Epidemiology (ISSN-0899-823X) is published monthly by SLACK Incorporated, 6900 Grove Road, Thorofare, New Jersey 08086 Telephone (609) 848-1000

Copyright 1990: All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

Subscriptions: Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku Tokyo 134. Japan Subscription rates in the US and possessions: Individual: One year—\$60.00. Two years—\$95.00. Three years—\$125.00. Institutional: One year—\$70.00. Two years—\$110.00. Three years—\$150.00; Canada \$18.00 additional each year; all other countries \$30.00 additional each year. Single copies of current issues may be obtained for \$8.00, United States and possessions; \$16.00 all other countries.

Reprints: All requests to reprint or use material published herein should be addressed to Lester J Robeson, SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08066. For reprint orders and prices, contact Joanne Patterson at (609) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy plus \$15 per page is paid directly to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

Change of address: Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Second-class postage is paid at Thorofare, New Jersey 08086 and additional entry points. Postmaster: Send address changes to SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086.

As of Volume 1, Number 1, INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in *Index Medicus*, *Current Contents—Clinical Practice Hospital Literature Index*, *Cumulative Index to Nursing and Allied Health Literature*, and *Nursing Abstracts*.

EDITORIAL OFFICES

Vanderbilt University School of Medicine
 A-1131 Medical Center North
 Nashville, TN 37232-2637
 (615) 343-1095; (615) 343-1882 (FAX)
 Email: iche@mcmail.vanderbilt.edu

EDITOR

Michael D. Decker, MD, MPH

MANAGING EDITOR

Susan Cantrell

STATISTICAL EDITOR

Beverly G. Mellen, PhD

SENIOR ASSOCIATE EDITORS

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

ASSOCIATE EDITORS

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

SECTION EDITORS**Beyond Infection Control:****The New Hospital Epidemiology**

Bryan P. Simmons, MD

Stephen B. Kritchevsky, PhD

Memphis, Tennessee

Wing Hong Seto, MD

Hong Kong

Disinfection and Sterilization

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

Emerging Infectious Diseases

Larry J. Strausbaugh, MD

Portland, Oregon

Robert W. Pinner, MD

Atlanta, Georgia

From the Laboratory

Marcus Zervos, MD

Royal Oak, Michigan

Fred C. Tenover, PhD

Atlanta, Georgia

Information Management

John A. Sellick, DO

Buffalo, New York

The International Perspective

Mary D. Nettleman, MD, MS

Richmond, Virginia

Issues in Surgery

James T. Lee, MD, PhD

St. Paul, Minnesota

Medical News

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

Practical Healthcare Epidemiology

Loreen A. Herwaldt, MD

Iowa City, Iowa

SHEA News

Murray D. Batt, MD

Clarksburg, West Virginia

Statistics for Hospital Epidemiology

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

Topics in Long-Term Care

Philip W. Smith, MD

Omaha, Nebraska

Topics in Occupational Medicine

David Weber, MD, MPH

Chapel Hill, North Carolina

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY[®]

EDITORIAL ADVISORY BOARD

- Jacques F. Acar, MD Paris, France
 J. Wesley Alexander, MD Cincinnati, Ohio
 Paul Arnow, MD Chicago, Illinois
 Graham A.J. Ayliffe, MD Birmingham, United Kingdom
 Neil L. Barg, MD Yakima, Washington
 Elizabeth Ann Bolyard, RN, MPH, CIC Atlanta, Georgia
 John M. Boyce, MD Providence, Rhode Island
 Professor Dr. Ilja Braveny Munich, Federal Republic of Germany
 Charles Bryan, MD Columbia, South Carolina
 Christian Brun-Buisson, MD Creteil, France
 Donald E. Craven, MD Boston, Massachusetts
 Sue Crow, MSN, RN, CIC Shreveport, Louisiana
 Franz Daschner, MD Freiburg, Federal Republic of Germany
 Leigh G. Donowitz, MD Charlottesville, Virginia
 Charles E. Edmiston, Jr., PhD Milwaukee, Wisconsin
 Theodore C. Eickhoff, MD Denver, Colorado
 Bruce Farber, MD Manhasset, New York
 Victoria J. Fraser, MD St. Louis, Missouri
 Peter C. Fuchs, MD, PhD Black Butte, Oregon
 Richard A. Garibaldi, MD Farmington, Connecticut
 Velvl Greene, PhD, MPH Beer Sheva, Israel
 Robert Gaynes, MD Atlanta, Georgia
 David W. Gregory, MD Nashville, Tennessee
 David K. Henderson, MD Bethesda, Maryland
 Peter N.R. Heseltine, MD Los Angeles, California
 Karen Hoffmann, RN, CIC, MS Chapel Hill, North Carolina
 Marguerite McMillan Jackson, RN, PhD San Diego, California
 Janine Jagger, MPH, PhD Charlottesville, Virginia
 William R. Jarvis, MD Atlanta, Georgia
 Douglas S. Kernodle, MD Nashville, Tennessee
 Robert H. Latham, MD Nashville, Tennessee
 Lewis B. Lefkowitz, MD Nashville, Tennessee
 Hsieh-Shong Leu, MD, MSc Taipei, Taiwan
 Jack Levy, MD Brussels, Belgium
 Victor Lorian, MD Bronx, New York
 Dennis G. Maki, MD Madison, Wisconsin
 Professor Dr. Walter Marget Munich, Federal Republic of Germany
 William J. Martone, MD Bethesda, Maryland
 Allison McGeer, MD Toronto, Ontario, Canada
 John E. McGowan, Jr., MD Atlanta, Georgia
 Jonathan L. Meakins, MD, DSc Montreal, Quebec, Canada
 Raf Mertens, MD Brussels, Belgium
 Robert R. Muder, MD Pittsburgh, Pennsylvania
 Joseph M. Mylotte, MD, CIC Buffalo, New York
 Lindsay Nicolle, MD Winnipeg, Manitoba, Canada
 Juhani Ojajarvi, MD Helsinki, Finland
 Michael T. Osterholm, PhD, MPH Minneapolis, Minnesota
 Jan Evans Patterson, MD San Antonio, Texas
 Sindy M. Paul, MD Trenton, New Jersey
 Michael A. Pfaller, MD Iowa City, Iowa
 Samuel Ponce de Leon, MD, MSc Mexico City, Mexico
 Isaam Raad, MD Houston, Texas
 Manfred L. Rotter, MD, DipBact Vienna, Austria
 Theodore Sacks, MD Jerusalem, Israel
 William E. Scheckler, MD Madison, Wisconsin
 Kent Sepkowitz, MD New York City, New York
 Denis Spelman, MD Prahran Victoria, Australia
 Michael L. Tapper, MD New York, New York
 Clyde Thornsberry, PhD Brentwood, Tennessee
 Professor Leonid P. Titov Minsk, Republic of Belarus
 Timothy R. Townsend, MD Millwood, Virginia
 Antoni Trilla, MD, PhD Barcelona, Spain
 Professor Wang Shu-Qun Beijing, People's Republic of China
 J. John Weems, Jr., MD Greenville, South Carolina
 Robert A. Weinstein, MD Chicago, Illinois
 Professor Dr. W. Weuffen Greifswald, Federal Republic of Germany
 Sergio B. Wey, MD São Paulo, Brazil
 Rebecca Wurtz, MD Evanston, Illinois

SLACK Incorporated

6900 Grove Road
 Thorofare, New Jersey 08086
 (609) 848-1000

Vice President/Group Publisher

Richard N. Roash

Publisher

John C. Carter

Editorial Director

Jennifer Kilpatrick

Production Editor

Shirley P. Strunk, ELS

Assistant Editor

Eileen C. Anderer

Circulation Manager

Lester J. Robeson, CCCC

Production Director

Christine Malin

Production Coordinator

Joanne Patterson

Publishing Director/ Advertising

Wayne McCourt

Pharmaceutical Group Sales Director

Michael LoPresti

Advertising Sales Representative

Jennine Kane

Classified/Recruitment Sales Manager

Michele Burch

"Synergism.."

Synergism is the working relationship between two ingredients which results in performance superior to that achieved by each ingredient working separately.

Synergism is Sporicidin. Glutaraldehyde combined with an alkaline phenate system produces superior disinfecting properties.* Patented Sporicidin disinfects with substantially less glutaraldehyde than other products.

Synergism makes Sporicidin tuberculocidal in only ten minutes at room temperature, 68° F and above, when diluted 1:16. Other alkaline glutaraldehyde products cannot be diluted and/or require longer contact times with heating to 77° F.


Sporicidin fulfills the CDC definition of high level disinfection using the lowest concentration of glutaraldehyde... because of Synergism.

* Journal of Clinical Microbiology,
November 1985, p. 735 - 739



Sporicidin
INTERNATIONAL

10 Old Georgetown Road, Rockville, Maryland 20847



© 1990 Winthrop Pharmaceuticals



Leading the way to...

A safer future

Provides a safer environment to reduce the risk of needle-stick injuries

From injection to disposal, CARPUJECT protects you from accidental needle sticks by minimizing exposure to contaminated needles.

Chosen for safety by nurses nationwide

In a national survey, nurses overwhelmingly preferred CARPUJECT over Tubex** for protection from patients' blood. CARPUJECT was also preferred in all of 8 other criteria, ranging from convenience to efficiency.

Safer and more efficient than ampules and multi-dose vials

CARPUJECT increases efficiency and decreases risks with a sterile, accurate unit dose.

*Tubex® is a registered trademark of
Wyeth-Ayerst Laboratories

Wythrop Pharmaceuticals
Division of Tealco Drug Inc.
New York, NY 10016

CIDEX* is safe for scopes. Don't take our word for it.

Take theirs.

Karl Storz


Circon ACMI

Circon ACMI

Pentax

Olympus

Fujinon



Major scope manufacturers have always recommended CIDEX* Activated Dialdehyde Solution.† Research and more than 20 years of actual use have shown that nonsurfactant CIDEX Solution safely disinfects delicate fiberoptic equipment. *Take their word for it: When it comes to scopes, there's no safer high-level disinfectant available.* CIDEX. We go back a long way.



Johnson & Johnson
MEDICAL INC.

* TRADEMARK © J.J.M. INC. 1990. ARLINGTON, TEXAS 76004-0130

† Recommendations of scope manufacturers are based on scope compatibility to CIDEX* Activated Dialdehyde Solution